India’s First Dedicated Myeloma & Lymphoma Centre Opens in Gurugram

Gurugram – In a move that could reshape the haematology‑oncology landscape across the sub‑continent, a flagship hospital in Gurugram announced the launch of India’s very first dedicated centre for myeloma and lymphoma. The facility, unveiled last week, brings together a suite of specialists, state‑of‑the‑art equipment, and research initiatives under one roof.

While many cancer centres treat a broad spectrum of tumours, this new unit zeroes in on plasma‑cell disorders (myeloma) and lymphoid malignancies (lymphoma). The idea, hospital administrators say, is simple: depth of focus can translate into better outcomes. “When you concentrate expertise, you reduce diagnostic delays, tailor therapies more precisely, and ultimately give patients a fighting chance,” explained Dr. Neha Sharma, the centre’s medical director.

The centre is staffed by a multidisciplinary team that includes haematologists, radiation oncologists, transplant surgeons, radiologists, and supportive‑care professionals such as dietitians and psychologists. This collaborative model mirrors leading international institutions, allowing for rapid tumour‑board discussions and coordinated care plans.

From a technological standpoint, the unit boasts next‑generation imaging (PET‑CT, whole‑body MRI) and a modern laboratory capable of performing cytogenetic profiling, next‑generation sequencing, and minimal residual disease monitoring. “These tools help us understand the biology of each patient’s disease in real‑time, which is crucial for selecting the right targeted therapy,” said Dr. Arjun Mehta, head of the molecular diagnostics lab.

Beyond treatment, the centre places a strong emphasis on patient education and psychosocial support. Dedicated counsellors run weekly support groups, while an on‑site pharmacy ensures timely access to novel agents, including CAR‑T therapies that are just beginning to reach Indian patients.

Hospital leadership is also keen on research. The centre will act as a hub for clinical trials, inviting both national and global investigators to test new drugs and combination regimens. “We want to be not just a treatment centre but a knowledge engine that feeds advancements back into the wider community,” noted Dr. Sharma.

Early response to the launch has been overwhelmingly positive. Families of patients travelling from neighboring states have expressed relief at having a specialised hub so close to Delhi‑NCR. “When we heard about a place that focuses just on myeloma, we felt a weight lift off our shoulders,” shared a patient’s spouse, who prefers to remain anonymous.

As the centre settles into its routine, the hope is that its model will inspire similar initiatives in other metros, gradually building a network of dedicated haematology‑oncology units across India. For now, Gurugram’s new facility stands as a beacon of hope for thousands battling blood‑cancer diseases.